Docetaxel labeled with radionuclide shows high efficiency against cervical cancer cell lines in vitro

Abstract

We present a new treatment modality : docetaxel labeled with radionuclide iodine 131 in treatment of the HeLa Hep2 cell lines during 48 hours. Our result show that 131 I-docetaxel unlike non labeled docetaxel holds a promising therapeutic potential.

Keywords

• cervical cancer
• docetaxel
• radiolabeled docetaxel
• p53
• apoptosis
• chemosensitivity